HIGH-DOSE RITUXIMAB IN THE CONDITIONING REGIMEN BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED B-CELL LYMPHOMAS IS ASSOCIATED WITH REDUCED GVHD-RELATED DEATHS, BUT DID NOT IMPROVE DISEASE CONTROL

被引：0
|
作者：
Dodero, A. [1 ]
Spina, F. [1 ]
Sarina, B. [2 ]
Carniti, C. [1 ]
Patriarca, F. [3 ]
Carella, A. M. [4 ]
Levis, A. [5 ]
Bosi, A. [6 ]
Falda, M. [7 ]
Di Raimondo, F. [8 ]
Di Bartolomeo, P. [9 ]
Dalto, S. [1 ]
Bacigalupo, A. [10 ]
Rambaldi, A. [11 ]
Corradini, P. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Ematol, Milan, Italy
[2] Humanitas Canc Ctr, Ematol, Rozzano, Italy
[3] Univ Udine, I-33100 Udine, Italy
[4] IRCCS Casa Solievo della Sofferenza, San Giovanni Rotondo, Italy
[5] Osped Alessandria, Ematol, Alessandria, Italy
[6] Azienda Osped Univ Carreggi, Ematol, Florence, Italy
[7] Osped San Giovanni Battista Torino, Ematol, Turin, Italy
[8] Osepedale Ferrarotto, Ematol, Catania, Italy
[9] Osped Pescara, Ematol, Pescara, Italy
[10] Osped San Martino Genova, Ematol, Genoa, Italy
[11] Osped Papa Giovanni XXIII, Ematol, Bergamo, Italy
来源：
BONE MARROW TRANSPLANTATION | 2014年 / 49卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
PH-P393
引用
收藏
页码：S288 / S288
页数：1
相关论文
共 50 条
  • [31] Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias
    Massenkeil, G
    Nagy, M
    Neuburger, S
    Tamm, I
    Lutz, C
    le Coutre, P
    Wernecke, K
    Dörken, B
    Charité, RA
    BONE MARROW TRANSPLANTATION, 2005, 35 : S197 - S197
  • [32] Treosulfan-based tandem high-dose chemo-immuno-therapy with autologous stem cell transplantation for relapsed and refractory aggressive B-cell lymphomas.
    Reichle, A
    Holler, E
    Berand, A
    Andreesen, R
    BLOOD, 2005, 106 (11) : 460B - 460B
  • [33] High-dose etoposide, cytarabine and melphalan as conditioning regimen for autologous stem cell transplantation in patients with refractory or relapsed Hodgkin's lymphoma
    Bekadja, M. A.
    Osmani, S.
    Brahimi, M.
    Talhi, S.
    Bekadja, S.
    Belkhodja, S.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S446 - S446
  • [34] High-dose chemotherapy followed by autologous stem-cell transplantation for Hodgkin disease using CVB as conditioning regimen
    Avila, R. A.
    Valdez, J. A.
    Caeiro, G.
    Basquiera, A. L.
    Sturich, A. G.
    Berretta, A. R.
    Garcia, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
    Anderlini, P
    Saliba, R
    Acholonu, S
    Okoroji, GJ
    Donato, M
    Giralt, S
    Andersson, B
    Ueno, NT
    Khouri, I
    De Lima, M
    Hosing, C
    Cohen, A
    Ippoliti, C
    Romaguera, J
    Rodriguez, MA
    Pro, B
    Fayad, L
    Goy, A
    Younes, A
    Champlin, RE
    BONE MARROW TRANSPLANTATION, 2005, 35 (10) : 943 - 951
  • [36] Addition of Rituximab in Reduced Intensity Conditioning Regimens for B-Cell Malignancies Does Not Influence Transplant Outcomes: EBMT Registry Analyses Following Allogeneic Stem Cell Transplantation for B-Cell Malignancies
    Tomaszewska, Agnieszka
    Jagasia, Madan
    Beohou, Eric
    van der Werf, Steffie
    Blaise, Didier
    Kanfer, Edward
    Milpied, Noel
    Remenyi, Peter
    Ciceri, Fabio
    Bourhis, Jean H.
    Chevallier, Patrice
    Solano, Carlos
    Socie, Gerard
    Bruno, Benedetto
    Rambaldi, Alessandro
    Castagna, Luca
    Kroger, Nicolaus
    Corradini, Paolo
    Afanasyev, Boris
    Ladetto, Marco
    Niederwieser, Dietger
    Scheid, Christof
    Sengeloev, Henrik
    Kroschinsky, Frank
    Yakoub-Agha, Ibrahim
    Schoemans, Helene
    Koenecke, Christian
    Penack, Olaf
    Peric, Zinaida
    Greinix, Hildegard
    Duarte, Rafael F.
    Basak, Grzegorz W.
    FRONTIERS IN IMMUNOLOGY, 2021, 11
  • [37] Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
    P Anderlini
    R Saliba
    S Acholonu
    G-J Okoroji
    M Donato
    S Giralt
    B Andersson
    N T Ueno
    I Khouri
    M De Lima
    C Hosing
    A Cohen
    C Ippoliti
    J Romaguera
    M A Rodriguez
    B Pro
    L Fayad
    A Goy
    A Younes
    R E Champlin
    Bone Marrow Transplantation, 2005, 35 : 943 - 951
  • [38] Cure of a patient with profoundly chemotherapy-refractory primary mediastinal large B-cell lymphoma: Role of rituximab, high-dose therapy, and allogeneic stem cell transplantation
    Nath, SV
    Seymour, JF
    LEUKEMIA & LYMPHOMA, 2005, 46 (07) : 1075 - 1079
  • [39] Bortezomib after high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with multiple myeloma: A comparison with the historical conditioning regimen with melphalan alone
    Ferini, G. A.
    Arbelbide, J. A.
    Basquiera, A. L.
    Nucifora, E.
    Schutz, N.
    Otero, V.
    Fantl, D.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S461 - S462
  • [40] Mabtera (rituximab) treatment of patients with refractory B-cell lymphomas on high-dose chemotherapy with autologous transplantation of hemopoiesis precursor cells
    Ptushkin, VV
    Chimishkyan, KL
    Zhukov, NV
    Osmanov, DS
    Andreeva, LY
    Tupitsyn, NN
    Larionova, VB
    Mkheidze, DM
    Poddubnaya, IV
    TERAPEVTICHESKII ARKHIV, 2003, 75 (01) : 65 - 68
12345